



Gubra concludes the research agreement with UK Biotech

Today, Gubra announces the finalization of its two-year explorative research agreement with Silence Therapeutics PLC that was signed in early 2022. The collaboration concerned early target discovery of RNAi therapies for liver diseases.

In collaboration with Silence Therapeutics, we have explored potential novel liver-targets for diseases with an unmet medical need. We have had a great collaboration with Silence Therapeutics, and both parties have completed the planned activities according to the research plan. Today, we have jointly decided not to further pursue any research activities under this collaboration and consequently Gubra does not expect future income from this collaboration.

Contacts at Gubra

Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586

Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra

Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-01-26 13:33 CET.

Attachments

[Gubra concludes the research agreement with UK Biotech](#)